Chemerin as a novel crevicular fluid marker of patients with periodontitis and type 2 diabetes mellitus

Background: The objectives of the present study are to: 1) determine whether gingival crevicular fluid (GCF) chemerin is a novel predictive marker for patients with chronic periodontitis (CP) with and without type 2 diabetes mellitus (T2DM); 2) analyze the relationship between chemerin and interleukin (IL)-6 in periodontally healthy individuals and in patients with CP and with and without T2DM; and 3) evaluate the effect of non-surgical periodontal therapy on GCF chemerin levels. Methods: Eighty individuals were split into four groups: 20 who were systemically and periodontally healthy (CTRL), 20 with T2DM and periodontally healthy (DM-CTRL), 20 systemically healthy with CP (CP), and 20 with CP and T2DM (DM-CP). Individuals with periodontitis were treated with non-surgical periodontal therapy. GCF sampling procedures and clinical periodontal measures were performed before and 6 weeks after treatment. Enzyme-linked immunosorbent assay was used to measure chemerin and IL-6 levels. Results: Greater values for GCF chemerin and IL-6 levels were found in CP groups than in periodontally healthy groups, inDM-CP than inCP, and in DM-CTRL than inCTRL (P